| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:26 | Neola Medical AB Q3 Sales Increase | 4 | RTTNews | ||
| 08:00 | Neola Medical AB: Neola Medical Q3 Report 2026 - FDA Breakthrough Device Designation strengthens U.S. regulatory pathway | 42 | GlobeNewswire (Europe) | During the third quarter, Neola Medical reached a major regulatory milestone as the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to Neola®. The designation recognizes... ► Artikel lesen | |
| 04.09. | Neola Medical AB: Neola Medical Receives FDA Breakthrough Device Designation | 310 | GlobeNewswire (Europe) | Neola Medical AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Neola®, the Company's medical device for non-invasive, continuous... ► Artikel lesen | |
| 31.08. | Neola Medical AB: Neola Medical Granted U.S. Design Patent Strengthening Protection of Neola User Interface | 297 | GlobeNewswire (Europe) | Neola Medical AB (publ) today announces that the United States Patent and Trademark Office (USPTO) has granted the company a design patent covering the graphical user interface of Neola®. The patent... ► Artikel lesen | |
| 20.08. | Neola Medical weitet Verlust in Q2 2026 aus - Aktie gibt nach | 5 | Investing.com Deutsch | ||
| 20.08. | Neola Medical AB Q2 Loss Widens | 2 | RTTNews | ||
| 20.08. | Neola Medical AB: Neola Medical Q2 Report 2026 - Clinical progress, secured financing and sharpened focus | 224 | GlobeNewswire (Europe) | During the quarter, Neola Medical reported positive safety results from its first clinical pilot study in preterm born babies in Sweden. The study confirmed a favorable safety profile of Neola® and... ► Artikel lesen | |
| 10.06. | Neola Medical AB: Neola Medical granted Patent in the U.S. for reducing optical noise in lung monitoring measurements | 209 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted a patent in the U.S. for a technical solution that reduces noise in measurements for continuous lung monitoring. The patent protects an innovation designed to... ► Artikel lesen | |
| NEOLA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.06. | Listing of subscription rights and paid subscription shares of Neola Medical AB | 356 | GlobeNewswire | With effect from June 03, 2026, the subscription rights in Neola Medical AB will be traded on First North Growth Market. Trading will continue up until and including June 12, 2026.
... ► Artikel lesen | |
| 19.05. | Neola Medical AB: Neola Medical Q1 Report 2026 - Positive safety results from clinical study in preterm born babies strengthen the path toward market | 250 | GlobeNewswire (Europe) | During the quarter, Neola Medical completed enrollment and reported positive safety results from its first clinical pilot study in preterm born babies in Sweden. The study confirmed a favorable safety... ► Artikel lesen | |
| 21.04. | Neola Medical AB: Neola Medical Reports Positive Safety Results from First Clinical Pilot Study and Advances Towards Next Phase of Clinical Development | 229 | GlobeNewswire (Europe) | Neola Medical today announces final results from its clinical pilot study, confirming a favorable safety profile of Neola® across the studied patient population, including very low birth weight preterm... ► Artikel lesen | |
| 16.03. | Neola Medical AB: Neola Medical Completes Enrollment in Swedish Clinical Pilot Study | 500 | GlobeNewswire (Europe) | Neola Medical announces completion of patient enrollment in its clinical pilot study on preterm born babies in Sweden. All ten babies have now been included in the study, marking an important milestone... ► Artikel lesen | |
| 12.02. | Neola Medical AB: Neola Medical Q4 Report 2025 - Advancing IP Protection as a Core Strategic Asset across Key Markets | 230 | GlobeNewswire (Europe) | During the quarter four new patents were granted, adding in total of seven new patent grants during 2025. This marks Neola Medical's strongest year to date in terms of IP protection across all key target... ► Artikel lesen | |
| 02.12.25 | Neola Medical AB: Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market | 259 | GlobeNewswire (Europe) | Neola Medical AB (publ) announces today that the company has been granted a U.S. patent protecting its disposable probes for the medical device Neola®. The advanced light and detector probes are used... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LIFESTANCE HEALTH GROUP | 14,170 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 69,84 | +0,01 % | BrightSpring, Centene stand out as healthcare's most persistent Strong Buys | ||
| HEARTFLOW | 47,040 | -0,06 % | Heartflow stock tumbles despite strong growth beating Q3 expectations | ||
| GENEDX | 47,335 | +0,10 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:... ► Artikel lesen | |
| BILLIONTOONE | 97,56 | 0,00 % | BillionToOne auf der Stifel Healthcare Conference 2026: Wachstumsdynamik gewinnt an Breite | ||
| FRESENIUS MEDICAL CARE | 39,360 | -0,88 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius kündigt Verkauf von rund 13,4 Millionen Aktien der Fresenius Medical Care AG an - Finanzbeteiligung soll auf rund 20 Prozent sinken | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Sonstiges
Fresenius kündigt Verkauf von rund 13,4 Millionen Aktien der Fresenius Medical Care AG an - Finanzbeteiligung soll... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 7,625 | 0,00 % | Morning Market Movers: Veea, NFT Limited, WISeSat.Space, Alignment Healthcare See Big Swings | NEW YORK CITY (dpa-AFX) - At 8:15 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 11,655 | 0,00 % | RBC Capital reiterates Aveanna Healthcare stock rating at Outperform | ||
| SIEMENS HEALTHINEERS | 43,690 | +0,90 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Siemens Healthineers nach Zahlen zum vierten Geschäftsquartal 2025/26 von 39 auf 43 Euro angehoben, aber die Einstufung auf... ► Artikel lesen | |
| PROGYNY | 36,700 | 0,00 % | Rekorde bei Familienplanung: Progyny glänzt mit blitzsauberer Bilanz und massiven Rückkäufen | Hier an der Wall Street in New York wird oft das schnelle Geld gesucht. Doch die wahren Börsenperlen findet man häufig in lukrativen Nischen, in denen ein Unternehmen zum unverzichtbaren Marktführer... ► Artikel lesen | |
| FRESENIUS | 54,09 | +0,63 % | BARCLAYS stuft Fresenius SE auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Fresenius von 58,50 auf 65,00 Euro angehoben und die Einstufung auf "Overweight" belassen. Der Deal mit WuXi Biologics... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 23,790 | 0,00 % | Procept BioRobotics outlines $390M-$410M 2026 revenue, while targeting positive adjusted EBITDA in Q4 | ||
| PRIVIA HEALTH GROUP | 25,000 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 33,800 | -1,74 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 27 auf 26 Euro gekappt und die Aktien von "Equal Weight" auf "Underweight" abgestuft. Dem... ► Artikel lesen | |
| STARLING ONCOLOGY INSTITUTE | 3,395 | 0,00 % | NSE - Starling Oncology, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |